Doublet or Triplet Antiemetic Prophylaxis for Nausea and Vomiting Induced by Trastuzumab Deruxtecan: an Open-Label, Randomized, and Multicenter Exploratory Phase 2 Study

Background: Trastuzumab deruxtecan is classified as an anticancer agent that poses a moderate emetic risk in the international guidelines for antiemetic therapy. The guidelines recommend emesis prophylaxis using a two-drug combination therapy comprising a 5-hydroxytryptamine-3 receptor antagonist (5...

Descripción completa

Detalles Bibliográficos
Autores principales: Iihara, Hirotoshi, Shimokawa, Mototsugu, Bando, Hiroko, Niwa, Yoshimi, Mizuno, Yutaka, Kawaguchi, Yoshihiro, Kitahora, Mika, Murakami, Akari, Kawai, Masaaki, Ishida, Kazushige, Takeuchi, Makoto, Ishihara, Kazuhiro, Iyoda, Tomokazu, Nakada, Takumi, Ogiso, Atsuko, Kojima, Yasuyuki, Kumagai, Fumiyoshi, Sawa, Aya, Mori, Ryutaro, Higuchi, Kosuke, Furuta, Tomoko, Kamei, Yoshiaki, Tsuchiya, Masami, Terasaki, Azusa, Yamamoto, Senri, Kitazawa, Mai, Okazaki, Mai, Suzuki, Akio, Futamura, Manabu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539399/
https://www.ncbi.nlm.nih.gov/pubmed/37779870
http://dx.doi.org/10.7150/jca.87169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539399/
https://www.ncbi.nlm.nih.gov/pubmed/37779870
http://dx.doi.org/10.7150/jca.87169

Ejemplares similares